Stock comparison
Veracyte
VCYT$3.07BHealthcare Market cap, Sector
Viking Therapeutics
VKTX$3.33BHealthcare Market cap, Sector
Overall winner
Veracyte
VCYT 70 VKTX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
VCYT7wins
0winsVKTX
50D
F18
61C
D53
65C
F36
72B
F10
50D
F0
51D
F24
56D
F28
Side-by-side metrics
| Metric | VCYT | VKTX |
|---|---|---|
| Market cap | $3.07B | $3.33B Winner |
| P/E (TTM) | 34.8x | - Winner |
| EV/EBIT | 38.4x | - Winner |
| ROIC (TTM) | Winner: 4.73% | -100.02% |
| Gross margin | Winner: 71.31% | 0.0% |
| Net margin | Winner: 16.25% | 0.0% |
| Revenue CAGR 5y | 23.89% | - |
| EPS CAGR 5y | - | - |
| Debt / Equity | 0.0x | - Winner |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
VCYT leads on
- ROIC (TTM)4.73%vs -100.02%+105%
- Gross margin71.31%vs 0.0%+100%
- Net margin16.25%vs 0.0%+100%
VKTX leads on
- EV/EBIT-vs 38.4x+121%
- P/E (TTM)-vs 34.8x+120%
- Debt / Equity-vs 0.0x+100%
- Market cap$3.33Bvs $3.07B+8%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.